Valye reports for unlimited access

Dollar General Corporation is a discount retailer operating primarily in the United States, offering a broad assortment of consumables, seasonal items, home products, and apparel at low prices. The company focuses on serving value-conscious consumers through a network of stores located mainly in rural and suburban areas. Dollar General's business model emphasizes cost efficiency, high inventory turnover, and a value proposition centered on convenience and affordability. The company maintains active oversight of operational risks including cybersecurity, with the Board's Audit Committee engaged in enterprise risk management and regular review of risk mitigation strategies [S1].

Victoria's Secret & Co. operates globally recognized intimate apparel brands Victoria's Secret and PINK, complemented by a beauty business and the direct-to-consumer brand Adore Me. The company sells through retail stores in North America and China, digital channels, and international partners across approximately 70 countries. Its business model emphasizes product innovation, brand differentiation, and omnichannel customer engagement. The company faces challenges from tariffs and a recent IT security incident but continues to execute a strategic growth plan called 'Path to Potential' focused on bra leadership, revitalizing PINK, expanding beauty, and evolving go-to-market strategies. Financially, the company reported increased net sales and gross profit in 2025, with solid liquidity and cash flow generation.

Milestone Pharmaceuticals Inc. is a clinical-stage pharmaceutical company specializing in the development and commercialization of etripamil, a nasal spray treatment for paroxysmal supraventricular tachycardia (PSVT). The company’s lead product, CARDAMYST, received FDA approval in December 2025 as the first self-administered nasal spray for PSVT and has since been launched commercially. Milestone does not own manufacturing facilities and relies on third-party manufacturers, with some suppliers located internationally, including China. The company has licensed rights for etripamil nasal spray delivery in China and related territories to Corxel, an affiliate of RTW Investments, and has monetized future royalties through a $75 million upfront payment from RTW. Financially, Milestone reported a net loss of $63.1 million for the fiscal year ended December 31, 2025, with strong liquidity ratios indicating a solid cash position. The company faces risks from regulatory approval processes, international trade policies, and evolving healthcare legislation affecting drug pricing and reimbursement.

InflaRx N.V. is a clinical-stage biopharmaceutical company listed on Nasdaq since 2017. The company primarily engages in research and development of therapeutic candidates, with a focus on inflammatory diseases. Its main product candidates include vilobelimab and izicopan, which are in various stages of clinical trials. InflaRx has not generated significant product revenue and relies on equity financing, government grants, and collaborations to fund operations. The company reported a net loss of €45.6 million for 2025 and held cash and short-term investments totaling approximately €46.4 million at year-end 2025. It has received regulatory notices related to its stock price and continues to manage risks related to clinical development, financing, and cybersecurity [S1][N1][N2].

Ermenegildo Zegna N.V. is a luxury fashion group with a leading position in high-end menswear and a portfolio of three complementary brands: ZEGNA, Thom Browne, and TOM FORD FASHION. The Group's vertically integrated supply chain, known as the Filiera, includes some of Italy's finest textile producers and luxury manufacturing facilities. The Group designs, produces, markets, and distributes luxury menswear, womenswear, footwear, leather goods, and accessories globally. It operates primarily through a direct-to-consumer (DTC) channel, comprising 471 directly operated stores worldwide as of December 31, 2025, supplemented by wholesale distribution in over 80 countries. The Group's revenues for 2025 were approximately €1.92 billion, with a net profit of €109.5 million. The Group's business is influenced by macroeconomic factors, consumer confidence, and international tourism, which affect discretionary spending on luxury goods. The Group has been focusing on expanding and strengthening its DTC channel, including converting wholesale stores to DTC and opening new locations. The acquisition of TOM FORD FASHION in 2023 expanded the Group's brand portfolio and product offerings. The Group maintains a net cash surplus and liquidity ratios indicating financial stability. Risks include macroeconomic uncertainty, inflationary pressures, geopolitical developments, and ongoing legal proceedings related to trademark disputes.

Belpointe PREP, LLC is a Delaware limited liability company and the successor to Belpointe REIT, Inc. It is externally managed by an affiliate of its sponsor and operates as a qualified opportunity fund investing primarily in commercial real estate and related assets within qualified opportunity zones. The company’s portfolio includes commercial, mixed-use, multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, data centers, and solar projects across the United States. It has two reportable segments: Commercial and Mixed-use. The company’s Class A units trade on the NYSE American under the ticker 'OZ'. It has raised significant capital through public offerings and calculates NAV quarterly. The company does not currently pay distributions and manages leverage with a target property-level range of 50-70%.

Pelican Acquisition Corp was incorporated in July 2024 in the Cayman Islands as a blank check company with the purpose of effecting a merger, share exchange, asset acquisition, or similar business combination. The company completed its initial public offering in May 2025, raising gross proceeds of $86.25 million plus a private placement, with funds held in a trust account for the benefit of public shareholders. The company’s sole activity since IPO has been identifying and evaluating acquisition candidates. In September 2025, it entered into a definitive business combination agreement with Greenland Exploration Limited and March GL Company. Upon closing, the company will domesticate to Texas and rename to Greenland Energy Company, with an expected Nasdaq listing. The management team comprises experienced professionals with backgrounds in real estate, law, corporate management, and international business. The company faces competition from other SPACs and investment entities in sourcing acquisition targets and must comply with Nasdaq rules requiring the initial business combination to meet minimum valuation thresholds. The company’s financial position as of January 31, 2026, shows limited liquidity and no operating revenue.

York Space Systems Inc. is a leading U.S. space and defense prime contractor focused on delivering mission-critical spacecraft and software solutions for national security and commercial markets. The company provides a vertically integrated technology stack encompassing spacecraft design, production, integration, and operation, enabling rapid deployment and lifecycle management of satellite constellations. York's spacecraft platforms—S-CLASS, LX-CLASS, and M-CLASS—are modular and share substantial hardware and software commonality, facilitating scalable, cost-effective solutions across a broad range of mission requirements. Proprietary software suites support autonomous mission planning, flight control, and ground operations, integrated with a global network of more than 45 ground antennas. York's business model includes recurring revenue from software and services alongside hardware replacement cycles. The company completed its IPO in January 2026 and maintains a significant backlog of contracts primarily with U.S. government defense customers.

Firefly Aerospace Inc. is a publicly traded aerospace company with recent SEC filings disclosing financial results for the fiscal year ended December 31, 2025. The company maintains substantial liquidity with cash and short-term investments totaling over $890 million and a current ratio above 4.5. Despite significant net losses reported in 2025, Firefly Aerospace is actively managing its capital structure, including an expanded revolving credit facility. Operationally, the company has appointed a new COO to lead production scaling efforts. Public disclosures do not provide detailed descriptions of the company's products, customers, or industry classification.

QIAGEN N.V. is a global provider of molecular diagnostics and life sciences tools, focusing on sample and assay technologies. The company files comprehensive annual (20-F) and quarterly (6-K) reports with the SEC, detailing its financial performance, business strategy, and operational environment. It emphasizes adjusted financial results to provide clarity on ongoing core operations, excluding certain non-recurring or non-operational costs. The company reported strong liquidity and profitability metrics for the fiscal year ended December 31, 2025. Recent corporate developments include an acquisition agreement for Parse Biosciences and a synthetic share repurchase plan. Leadership changes occurred with the CEO stepping down in late 2025. The company operates in a regulated environment with ongoing research and development efforts and holds significant intellectual property assets [S1][S2].

Cellectis S.A. operates as a clinical-stage biotechnology company focused on developing gene-edited allogeneic CAR T-cell therapies (UCART) for cancer treatment and gene therapy candidates for other diseases. Its proprietary gene-editing technology enables the creation of off-the-shelf CAR T-cell products derived from healthy donors, designed to improve safety and efficacy. The company manages its operations primarily through its Therapeutics segment, following the deconsolidation of its former Plants segment. Cellectis collaborates with partners such as AstraZeneca under joint research and collaboration agreements, which contribute significantly to its revenues. The company sponsors clinical trials for its UCART candidates and continues to develop manufacturing capabilities in France and the United States. It has incurred net losses historically, reflecting ongoing investment in research and development and clinical programs. Cellectis' securities are listed on Nasdaq and Euronext Growth Paris.

Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases. Its commercial portfolio includes eight FDA-approved products targeting endocrinology and metabolic rare diseases, such as INCRELEX® for severe primary IGF-1 deficiency, ALKINDI SPRINKLE® and KHINDIVI™ for adrenal insufficiency, GALZIN® for Wilson disease, and others for phenylketonuria, NAGS deficiency, homocystinuria, and tyrosinemia type 1. The company also has five late-stage development candidates, including ET-600 with a PDUFA date in early 2026, and others in clinical or preclinical stages. Eton leverages its business development expertise to acquire and advance under-appreciated assets, employs regulatory knowledge particularly in the FDA 505(b)(2) pathway, and maintains internal commercial operations with a sales force targeting specialty physicians and patient advocacy groups. Manufacturing is outsourced to qualified third-party CMOs in the US and Europe. The company reported $79.95 million in revenues for 2025, with significant growth in product sales and licensing revenue, but a net loss of $4.6 million. Cash and liquidity ratios indicate a moderate liquidity position as of year-end 2025 [S1].

Biofrontera Inc. develops, manufactures, and commercializes pharmaceutical products for dermatological conditions, focusing on photodynamic therapy (PDT). Its main products, Ameluz and the RhodoLED lamp series, treat actinic keratosis, a skin condition with pre-cancerous lesions. The company sells directly to dermatology offices in the U.S. and manages clinical trials through its subsidiary Discovery. In 2025, Biofrontera acquired full U.S. rights to Ameluz and RhodoLED and sold its Xepi product line asset. The company aims to expand sales in the U.S., pursue label extensions, and strategically manage its portfolio to support growth. It employs 92 people across the U.S. and Germany and maintains a diverse customer base. Financially, it reported a net loss in 2025 with moderate liquidity ratios. Recent clinical data and FDA regulatory progress support its product pipeline.

Assembly Biosciences, Inc. is a biotechnology company developing therapeutics targeting serious viral diseases with a focus on recurrent genital herpes, hepatitis delta virus (HDV), and hepatitis B virus (HBV). The company’s clinical-stage pipeline includes two long-acting helicase-primase inhibitors (HPIs) for recurrent genital herpes (ABI-1179 and ABI-5366), an orally bioavailable HDV entry inhibitor (ABI-6250), a next-generation capsid assembly modulator (ABI-4334) for HBV, and a broad-spectrum non-nucleoside polymerase inhibitor (ABI-7272) targeting transplant-related herpesviruses. Assembly has a collaboration agreement with Gilead Sciences, which exercised its option to license the HPI program in December 2025. The company reported positive Phase 1a/b clinical data for its HPI candidates, showing potent antiviral activity, favorable pharmacokinetics supporting once-weekly or once-monthly oral dosing, and good safety profiles. Assembly has no approved products and finances operations through equity and collaboration revenues. As of December 31, 2025, the company held approximately $248.1 million in liquid assets and reported a net loss of $6.12 million for the year. The company outsources manufacturing and employs 73 people primarily in South San Francisco, California.

RCI Hospitality Holdings, Inc. is a holding company operating live adult entertainment nightclubs and a military-themed restaurant and bar concept called Bombshells. As of September 30, 2025, it operated 71 establishments across 15 states, including 59 nightclubs and 11 Bombshells locations. The Nightclubs segment generates revenue primarily from alcoholic beverages, service charges, and food and merchandise sales, with a gross margin of approximately 88.6% in fiscal 2025. The Bombshells segment focuses on a dining and entertainment experience with military-themed décor and uniforms, generating revenue from alcoholic beverages and food, with a gross margin of about 76.1%. The company also operates a Media Group serving the adult nightclub and retail industries and licenses an energy drink brand. The company launched a five-year Back-to-Basics strategy in December 2024 to improve existing operations and allocate free cash flow among acquisitions, share buybacks, and dividends. It reported consolidated revenues of $279.4 million and diluted EPS of $1.23 for fiscal 2025. The company is publicly traded on Nasdaq under the ticker RICK.

Zura Bio Ltd is a clinical-stage biotechnology company developing novel and differentiated medicines targeting autoimmune and inflammatory diseases with significant unmet medical needs. The company focuses on immune-mediated diseases supported by translational and clinical evidence. Its lead product candidate, tibulizumab, is in ongoing Phase 2 clinical trials for systemic sclerosis (SSc) and hidradenitis suppurativa (HS). The company also has additional clinical-stage assets including crebankitug and torudokimab. Zura Bio does not own manufacturing facilities but relies on contract manufacturing organizations and contract research organizations to conduct its clinical development programs. The company completed a Business Combination in March 2023 and trades on Nasdaq under the ticker ZURA. It is classified as an emerging growth company and a smaller reporting company under SEC definitions. The company has not generated revenue to date and has incurred operating losses since inception.

Kohl's Corp operates as a retail company offering a broad range of merchandise including women's, men's, children's apparel, footwear, accessories, and home products. The company has a significant digital sales channel, which accounted for 29% of net sales in 2025. Kohl's operates over 1,100 Sephora at Kohl's shop-in-shop locations, enhancing its product offerings. The company manages inventory carefully to optimize gross margin and has been closing underperforming stores and e-commerce fulfillment centers to improve operational efficiency. Kohl's capital allocation focuses on investing in growth, paying dividends, reducing debt, and share repurchases. The company maintains liquidity with a current ratio of 1.46 and a strong cash position as of January 31, 2026.

Sprinklr, Inc. provides a Unified Customer Experience Management (Unified-CXM) platform designed to help enterprises manage customer interactions across digital and traditional channels. The AI-native platform supports collaboration across customer-facing teams such as Customer Service and Marketing, enabling seamless, personalized customer journeys. The platform processes massive volumes of conversational data daily and integrates AI capabilities including machine learning and large language models to deliver insights and automation. Sprinklr offers four main product suites: Service, Social, Insights, and Marketing, all unified on a single scalable platform with extensive integrations and compliance certifications. The company serves a global customer base across industries, including a significant portion of Fortune 100 companies, with a focus on expanding within existing customers and attracting new enterprise clients. The business model relies primarily on subscription revenue with additional professional services. Sprinklr maintains a direct sales organization supported by a diverse partner ecosystem. The company reported $857.2 million in revenue and $22.9 million net income for fiscal year 2026, with a strong liquidity position and ongoing investments in product innovation and market expansion [S1].

Rubrik, Inc. operates as a cybersecurity company focused on securing data and accelerating AI transformation through its proprietary Zero Trust Data Security platform. The company’s core offerings are the Rubrik Security Cloud (RSC), a cloud-native SaaS platform securing data across enterprise, cloud, SaaS, unstructured data, and identity providers, and the Rubrik Agent Cloud (RAC), an AI operations platform for managing AI agent lifecycle and mitigating risks. Rubrik’s platform architecture integrates time-series data and metadata with AI and machine learning to deliver cyber resilience, threat detection, and rapid recovery capabilities. The company employs a land and expand sales strategy, selling subscriptions primarily through direct sales and a partner ecosystem. Rubrik serves a broad customer base across multiple industries and geographies, with a focus on expanding SaaS solutions, innovating product leadership especially in generative AI security, and growing its global footprint. The company reported net losses in fiscal 2026 and maintains moderate liquidity. Key risks include market adoption challenges, competition, transition to SaaS revenue recognition, customer retention, and debt servicing risks.

Satellogic Inc. operates in the NewSpace sector as a vertically integrated Earth observation company. It designs, manufactures, and operates a constellation of high-resolution satellites to provide geospatial data and analytics. The company’s business is organized into two main lines: Data & Analytics, which includes products like Aleph Observer for persistent site monitoring and Constellation as a Service, and Space Systems, which involves satellite sales and turnkey space programs. Satellogic’s technology features patented camera designs that capture significantly more imagery than competitors, a non-ITAR design facilitating sovereign satellite programs, and AI-enabled onboard analytics. The company’s constellation includes 17 operational satellites and two in commissioning as of December 31, 2025, with plans for an AI-First Merlin constellation and a NextGen platform with 30cm-class resolution. Revenues in 2025 were $17.7 million, primarily from government, defense, and intelligence customers, with a growing commercial focus. Satellogic maintains strong liquidity with $94.4 million in cash and equivalents and a current ratio above 5. The company has recently raised capital through registered direct offerings and announced further share offerings. Its sales cycle is long and involves significant effort, focusing on expanding government and commercial customer bases globally.

Snail, Inc. is a leading global independent developer and publisher of interactive digital entertainment across consoles, PCs, and mobile devices. Its flagship ARK franchise is a top-ranked sandbox survival game with over 108.6 million installs and substantial daily active users. The company operates three publishing labels targeting diverse market segments, including AAA and indie titles. Snail utilizes proprietary technology such as a versatile game engine, advanced server infrastructure, AI-driven development tools, and a micro-influencer marketing platform called NOIZ. The company fosters collaborative partnerships with development studios, providing capital, technology, and marketing support while preserving creative autonomy. In 2025, Snail released multiple ARK DLC expansions, expanded its mobile footprint, acquired new games, and advanced initiatives in Film, TV, and digital assets including a proprietary stablecoin. The company reported $81.2 million in net revenue and a net loss of $27.2 million for 2025, with liquidity ratios indicating current challenges. Snail’s business model is heavily reliant on the ARK franchise and third-party platform providers for distribution and monetization.

ONE Group Hospitality, Inc. is a hospitality company operating multiple restaurant brands including STK, Benihana, Kona Grill, and RA Sushi. The company operates 158 venues across North America, Europe, and the Middle East, including owned, managed, licensed, and franchised locations. STK is positioned as a modern American steakhouse with a high-energy social atmosphere, while Benihana offers interactive teppanyaki dining experiences. The company emphasizes a capital-light growth strategy, expanding through franchising and management agreements. Marketing efforts leverage digital, social media, and local advertising to build brand awareness and drive customer traffic. The business is subject to seasonal fluctuations and intense competition from other upscale dining and hospitality concepts. The company reported $805.7 million in revenue and a net loss of $92.2 million for fiscal 2025, with liquidity ratios indicating tight short-term financial flexibility as of year-end 2025.

GENELUX Corp focuses on developing next-generation oncolytic viral immunotherapies targeting aggressive and difficult-to-treat tumors. Its lead product candidate, Olvi-Vec, is a genetically modified vaccinia virus designed to selectively kill tumor cells and stimulate a personalized immune response. The company is conducting multiple clinical trials, including a Phase 3 registrational trial in platinum-resistant/refractory ovarian cancer, a Phase 2 trial in recurrent non-small cell lung cancer, and a Phase 1b/2 trial in China for recurrent small cell lung cancer. GENELUX operates a cGMP manufacturing facility in San Diego and has a strategic licensing and development partnership with Newsoara BioPharma for the Chinese market. The company has not yet commercialized any products and is building its capabilities for potential future commercialization.

American Battery Materials, Inc. operates as a U.S.-based renewable energy company specializing in the extraction, refinement, and distribution of lithium and magnesium minerals. The company holds 743 placer mining claims in the Lisbon Valley of Utah, acquired initially in 2021 and expanded in 2023. It is currently in the exploration stage with no commercial production or mineral reserves established. The company focuses on Direct Lithium Extraction (DLE) technology, which offers environmental and operational advantages over traditional mining methods. It has engaged technical consultants and plans to conduct extensive testing and resource estimation to advance its projects. The company has no current customers or off-take agreements and intends to use intermediaries for sales. It operates with a small team and emphasizes ESG principles. The lithium and magnesium markets are critical to U.S. national security, with government initiatives supporting domestic production. However, the company faces significant liquidity constraints and continues to incur losses while relying on capital markets for funding.

Mustang Bio, Inc. operates as a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for difficult-to-treat cancers, with a current emphasis on solid tumors. The company acquires rights to technologies through licensing or ownership interests, funds research and development, and aims to either out-license or commercialize these technologies. Mustang Bio’s development pipeline includes MB-101, a CAR T-cell therapy targeting IL13Rα2, and MB-108, an HSV-1 oncolytic virus, which are being developed in partnership with City of Hope National Medical Center and Nationwide Children’s Hospital. The combination therapy MB-109 is under regulatory review with the FDA, and clinical trials are planned. Mustang Bio has no approved products and has not generated revenue from product sales. The company has taken corporate actions including a reverse stock split, facility exit, asset divestment, and public offerings to support its operations and Nasdaq listing compliance.

Tigo Energy, Inc. operates in the solar energy sector, focusing on the design, development, and sale of solar hardware products, including Module Level Power Electronics (MLPE) and energy storage systems (GO ESS). The company also offers a SaaS platform called Predict+ and web-based monitoring services. Revenue is primarily generated through hardware sales to distributors, with additional income from royalties and software services. The company’s operations are global, with significant revenue contributions from EMEA, Americas, and APAC regions. Tigo Energy’s business model relies on contract manufacturing, with production concentrated in Thailand, China, and Vietnam, and it is subject to tariffs on imports into the U.S. The company is actively expanding its residential market presence in the U.S. and EMEA and investing in research and development to support new product introductions.

ACCESS Newswire Inc. is a company focused on press release distribution and related communications services. Its primary revenue driver is the ACCESSWIRE newswire brand, supplemented by sister platforms Newswire.com and PressRelease.com. The company has undergone growth through acquisitions and product enhancements, including virtual event products developed during the COVID-19 pandemic. It sold its Compliance business in February 2025, reallocating proceeds to debt reduction. The company recognizes subscription and service contract revenues ratably over contract terms, which can delay the impact of sales fluctuations on reported results. It operates in a highly competitive environment with competitors possessing greater resources and longer histories. The company has expanded its workforce significantly since 2012 and continues to invest in sales, marketing, and technology development. It is subject to various operational, competitive, regulatory, and financial risks, including those related to technology reliability, data security, and managing growth and acquisitions.

Research Frontiers Inc. develops and licenses patented SPD-Smart light-control technology used in various applications including aerospace, architectural, automotive, marine, and display products. The company licenses its technology to over 40 licensees worldwide, generating revenue primarily through license fees and royalties. Revenue recognition is based on three performance obligations: the grant of use of its patent portfolio, stand-ready technical support, and access to new intellectual property. The company’s royalty income is influenced by automotive industry trends and the adoption of SPD-SmartGlass technology in vehicle models. The company operates as a single segment and reports consolidated financial results. It has incurred recurring losses but maintains liquidity through equity financing and royalty collections. The company’s assets include property, equipment, and operating lease right-of-use assets located in the United States. It has a global revenue base with a majority generated outside the U.S.

Solid Biosciences Inc. focuses on developing gene therapies targeting rare genetic neuromuscular and cardiac diseases. Its pipeline includes candidates SGT-003, SGT-212, and SGT-501, with ongoing clinical trials such as INSPIRE DUCHENNE and IMPACT DUCHENNE. The company has received FDA orphan drug designations and fast track status for some candidates. It has not yet generated product revenue and continues to incur net losses. Solid Biosciences maintains strong liquidity as of the end of 2025 but anticipates the need for additional funding to advance its clinical programs and commercialization efforts. The company currently lacks internal sales and marketing infrastructure and may seek partnerships for commercialization.

Sky Harbour Group Corp is an aviation infrastructure developer focused on creating a nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages private and semi-private hangars at airports with significant based aircraft populations and high demand for hangar space. Its proprietary hangar designs accommodate larger jets with taller tail heights and winglets, addressing a shortage in suitable hangar infrastructure. Revenues derive mainly from long-term rental agreements, providing stable cash flows. As of December 31, 2025, the company operated 61 hangars totaling over 1 million rentable square feet with 78.1% occupancy and had 74 hangars under development or construction. The company finances development through bonds and bank debt and manages a diversified tenant base with staggered lease maturities.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops novel biologic therapeutic candidates using proprietary modular protein engineering platforms. The company was spun off from Inhibrx, Inc. in May 2024, acquiring assets related to its clinical programs and discovery pipeline. Its current clinical pipeline includes ozekibart (INBRX-109), a tetravalent DR5 agonist targeting cancer cells to induce apoptosis, and INBRX-106, a hexavalent OX40 agonist designed to enhance T-cell co-stimulation and anti-tumor immunity. Ozekibart is being investigated in multiple oncology indications including chondrosarcoma, Ewing sarcoma, and colorectal cancer, with positive clinical trial data reported. INBRX-106 is in early clinical development for solid tumors such as non-small cell lung cancer and head and neck squamous cell carcinoma. The company maintains in-house capabilities across discovery, protein engineering, clinical development, and commercialization, supported by a leadership team with extensive industry experience. Inhibrx reported $1.3 million in revenue and a net loss of $140.1 million for the fiscal year ended December 31, 2025, with a strong liquidity position and outstanding debt secured by company assets. The company is exploring strategic options for its lead program ozekibart to maximize value and accelerate development.

United States Antimony Corp is a mining and processing company focused on antimony, precious metals (gold and silver), and zeolite. It operates vertically integrated antimony processing facilities in Montana and Mexico, and a zeolite mining and processing facility in Idaho. The company has been expanding its mining claims in Alaska, Montana, Canada, and the southeastern U.S. It supplies antimony products used in flame retardants, batteries, ordnance, and other industrial applications primarily to customers in the U.S. and Canada. The company secured significant multi-year contracts in 2025, including a $248 million IDIQ contract with the U.S. Defense Logistics Agency. It is expanding processing capacity to support these contracts and has received government funding to modernize domestic production. The company’s stock began trading on the NYSE in March 2026. Financially, the company reported $39.3 million in revenues and a net loss of $4.3 million for 2025, with strong liquidity and increased working capital.

SELLAS Life Sciences Group, Inc. operates as a single segment biotechnology company focused on the development of novel therapeutics for cancer indications. The company’s clinical programs include the development of SLS009 and GPS, targeting acute myeloid leukemia and other cancers. SELLAS holds exclusive licenses for key technologies, including from GenFleet Therapeutics and Memorial Sloan Kettering Cancer Center, with milestone and royalty obligations contingent on development and sales outcomes. The company’s financial position as of December 31, 2025, shows a strong liquidity profile with over $71 million in cash and equivalents and a current ratio above 10, supporting ongoing clinical development activities. SELLAS has reported recurring net losses and negative cash flows from operations, consistent with its clinical-stage status. Recent strategic agreements and clinical trial progress have been publicly disclosed, reflecting active advancement of its pipeline.

Galecto, Inc. is a clinical-stage biopharmaceutical company engaged in developing treatments primarily for oncology, liver diseases, and rare diseases such as acute myeloid leukemia (AML). The company has undergone strategic shifts focusing on clinical-stage compounds including GB1211 and has acquired global rights to BRM-1420 and GB3226. In late 2025, Galecto completed a business combination with Damora Therapeutics, Inc., and subsequently changed its corporate name. The company has raised capital through a $275 million public offering in early 2026 to support its operations and clinical development programs. Financial disclosures indicate strong liquidity and ongoing net losses consistent with clinical-stage biopharmaceutical companies. The company is subject to typical industry risks including clinical development, regulatory approvals, and potential legal matters.

Harvard Apparatus Regenerative Technology, Inc. is a biotechnology company with two main operating segments: Regenerative Biotech, which focuses on developing regenerative medicine treatments for cancers, injuries, and birth defects of the gastrointestinal tract and airways, and Consumer Health Products, which markets dietary supplements primarily in Asia. The company’s consumer health products are distributed globally through an exclusive agreement with Health Regen, Inc. Revenue is recognized primarily upon delivery or availability of goods to customers or distributors. The company incurs research and development expenses related to its regenerative biotech segment and maintains manufacturing and office facilities in Holliston, MA. The company’s operations are subject to regulatory oversight by the FDA and foreign authorities, with associated compliance risks. The company reported product revenue of $704,000 in 2025, all from consumer health products, and a net loss of $6.87 million for the year ended December 31, 2025. Cash and short-term investments totaled approximately $2.55 million at year-end 2025, with a current ratio of 1.19. The company has ongoing clinical trials and research collaborations to advance its regenerative medicine pipeline.

electroCore, Inc. develops and commercializes bioelectronic therapies, including prescription devices such as gammaCore and Quell, targeting conditions like fibromyalgia and general wellness. The company has recently expanded its product portfolio to include general wellness and human performance products marketed under brands like Truvaga and TAC-STIM. Its sales are heavily concentrated in government healthcare channels, especially the U.S. Department of Veterans Affairs. electroCore relies on third-party manufacturers and distributors, including sole-source suppliers, for critical components and distribution outside the U.S. The company is actively expanding its direct-to-consumer sales channels and investing in commercial infrastructure to support growth. However, it faces challenges related to market acceptance, reimbursement coverage, supply chain reliability, and financial sustainability.